• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

正常造血祖细胞和恶性淋巴造血细胞对T细胞受体 - /CD3 - 、T细胞受体γδ + /CD3 + 和T细胞受体αβ + /CD3 + 淋巴细胞介导的直接细胞介导的MHC非限制性裂解表现出不同的敏感性。

Normal hematopoietic progenitor cells and malignant lymphohematopoietic cells show different susceptibility to direct cell-mediated MHC-non-restricted lysis by T cell receptor-/CD3-, T cell receptor gamma delta+/CD3+ and T cell receptor-alpha beta+/CD3+ lymphocytes.

作者信息

Voogt P J, Falkenburg J H, Fibbe W E, Veenhof W F, Hamilton M, Van Krimpen B A, Bolhuis R L

机构信息

Department of Hematology, University Medical Center, Leiden, The Netherlands.

出版信息

J Immunol. 1989 Mar 1;142(5):1774-80.

PMID:2521886
Abstract

To evaluate the capability of NK cells and cytotoxic T lymphocytes to interact with normal hematopoietic progenitor cells (HPC), as compared to neoplastic lymphohematopoietic cells, we investigated inhibition of colony growth of these cell populations in semi-solid culture systems, after incubation with cloned cytotoxic effector cells. Three different types of cloned effector cells were investigated: TCR-/CD3- NK cells, TCR-gamma delta+/CD3+ cells, and TCR-alpha beta+/CD3+ cytotoxic T lymphocytes. Effector cells showed differential levels of tumor cell colony inhibition, but no MHC-non-restricted lysis of normal HPC was observed. Pre-stimulation of normal HPC by culturing on established stromal layers had no effect. Cell-mediated lysis of HPC only occurred by Ag-specific MHC-restricted lysis by CTL, or by antibody-dependent cellular cytotoxicity. In cell mixing experiments, irradiated tumor cells, but not normal bone marrow cells inhibited tumor cell lysis. Furthermore, cloned effector lymphocytes were able to specifically eliminate malignant cells from tumor contaminated bone marrow without damaging normal HPC. When fresh leukemic cells were used as targets, growth of acute myeloblastic leukemia colonies was inhibited after incubation with several cytotoxic effector clones, whereas chronic myeloid leukemia precursor cells showed limited sensitivity to MHC-non-restricted cytolysis. These results indicate that MHC-non-restricted cytolysis by NK cells is selectively directed against neoplastic cells and not against normal HPC.

摘要

为了评估自然杀伤细胞(NK 细胞)和细胞毒性 T 淋巴细胞与正常造血祖细胞(HPC)相互作用的能力,并与肿瘤性淋巴造血细胞进行比较,我们在与克隆的细胞毒性效应细胞孵育后,研究了这些细胞群体在半固体培养系统中集落生长的抑制情况。研究了三种不同类型的克隆效应细胞:TCR-/CD3- NK 细胞、TCR-γδ+/CD3+细胞和 TCR-αβ+/CD3+细胞毒性 T 淋巴细胞。效应细胞对肿瘤细胞集落的抑制水平存在差异,但未观察到对正常 HPC 的 MHC 非限制性裂解。在已建立的基质层上培养对正常 HPC 进行预刺激没有效果。HPC 的细胞介导裂解仅通过 CTL 的 Ag 特异性 MHC 限制性裂解或通过抗体依赖性细胞毒性发生。在细胞混合实验中,经照射的肿瘤细胞而非正常骨髓细胞抑制了肿瘤细胞裂解。此外,克隆的效应淋巴细胞能够特异性地从肿瘤污染的骨髓中清除恶性细胞,而不损害正常 HPC。当使用新鲜白血病细胞作为靶标时,与几种细胞毒性效应克隆孵育后,急性髓性白血病集落的生长受到抑制,而慢性髓性白血病前体细胞对 MHC 非限制性细胞溶解的敏感性有限。这些结果表明,NK 细胞的 MHC 非限制性细胞溶解选择性地针对肿瘤细胞,而非正常 HPC。

相似文献

1
Normal hematopoietic progenitor cells and malignant lymphohematopoietic cells show different susceptibility to direct cell-mediated MHC-non-restricted lysis by T cell receptor-/CD3-, T cell receptor gamma delta+/CD3+ and T cell receptor-alpha beta+/CD3+ lymphocytes.正常造血祖细胞和恶性淋巴造血细胞对T细胞受体 - /CD3 - 、T细胞受体γδ + /CD3 + 和T细胞受体αβ + /CD3 + 淋巴细胞介导的直接细胞介导的MHC非限制性裂解表现出不同的敏感性。
J Immunol. 1989 Mar 1;142(5):1774-80.
2
Cytotoxic T lymphocyte triggering via CD16 is regulated by CD3 and CD8 antigens. Studies with T cell receptor (TCR)-alpha beta+/CD3+16+ and TCR-gamma delta+/CD3+16+ granular lymphocytes.通过CD16触发的细胞毒性T淋巴细胞受CD3和CD8抗原调节。对T细胞受体(TCR)-αβ+/CD3+16+和TCR-γδ+/CD3+16+颗粒淋巴细胞的研究。
J Immunol. 1990 May 1;144(9):3312-7.
3
Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes.通过CD8 +或CD4 +次要组织相容性抗原特异性细胞毒性T淋巴细胞识别克隆性白血病细胞、缓解期骨髓和HLA匹配供体骨髓。
J Clin Invest. 1995 Aug;96(2):877-83. doi: 10.1172/JCI118134.
4
Induction and blocking of cytolysis in CD2+, CD3- NK and CD2+, CD3+ cytotoxic T lymphocytes via CD2 50 KD sheep erythrocyte receptor.通过CD2 50KD绵羊红细胞受体诱导和阻断CD2⁺、CD3⁻自然杀伤细胞以及CD2⁺、CD3⁺细胞毒性T淋巴细胞中的细胞溶解作用
J Immunol. 1986 Jun 1;136(11):3939-44.
5
Induction of lysis by T cell receptor gamma delta+/CD3+ T lymphocytes via CD2 requires triggering via the T11.1 epitope only.T细胞受体γδ⁺/CD3⁺ T淋巴细胞通过CD2诱导细胞溶解仅需通过T11.1表位触发。
J Immunol. 1989 Mar 15;142(6):1797-802.
6
Multiple minor histocompatibility antigen-specific cytotoxic T lymphocyte clones can be generated during graft rejection after HLA-identical bone marrow transplantation.在 HLA 配型相同的骨髓移植后的移植物排斥反应过程中,可产生多种次要组织相容性抗原特异性细胞毒性 T 淋巴细胞克隆。
Bone Marrow Transplant. 1995 Jul;16(1):125-32.
7
TCR gamma delta cytotoxic T lymphocytes expressing the killer cell-inhibitory receptor p58.2 (CD158b) selectively lyse acute myeloid leukemia cells.表达杀伤细胞抑制受体p58.2(CD158b)的TCRγδ细胞毒性T淋巴细胞可选择性地裂解急性髓系白血病细胞。
Bone Marrow Transplant. 2001 May;27(10):1087-93. doi: 10.1038/sj.bmt.1703043.
8
Inhibition of non-MHC-restricted cytotoxicity by CD45 but not CD3 monoclonal antibodies in patients with large granular lymphoproliferative disease.在大颗粒淋巴细胞增殖性疾病患者中,CD45单克隆抗体而非CD3单克隆抗体对非MHC限制性细胞毒性具有抑制作用。
Clin Exp Immunol. 1989 Dec;78(3):396-401.
9
Antigen specific and MHC nonrestricted cytotoxicity of T cell receptor alpha beta+ and gamma delta+ human T cell clones isolated in IL-4.在白细胞介素-4中分离出的T细胞受体αβ+和γδ+人T细胞克隆的抗原特异性和MHC非限制性细胞毒性。
J Immunol. 1989 Jul 15;143(2):452-7.
10
Alloantigen-specific cytotoxic clones bearing the alpha,beta T cell antigen receptor but not CD4 or CD8 molecules.携带α、β T细胞抗原受体但不携带CD4或CD8分子的同种异体抗原特异性细胞毒性克隆。
J Immunol. 1990 Jul 15;145(2):470-6.

引用本文的文献

1
Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-alpha 2a and interleukin-2.接受重组人干扰素-α 2a和白细胞介素-2门诊细胞因子介导免疫治疗的血液系统恶性肿瘤患者的免疫学评估
Cancer Immunol Immunother. 1992;35(6):401-11. doi: 10.1007/BF01789019.